Lauren DiPetrillo, PhD

Phase 3 Safety and Tolerability Results of the Combination Olanzapine and Samidorphan in Patients With Schizophrenia: The 1 Year ENLIGHTEN-2-Extension

Background: Combination olanzapine and samidorphan (OLZ/SAM) is in development for treatment of schizophrenia and bipolar I disorder and is intended to provide the antipsychotic efficacy ...

Bei Yu , PhD;

Craig Hopkinson , MD;

Ying Jiang , PhD;

Christine Graham , PhD;

Bernard Silverman , MD;

Lauren DiPetrillo , PhD;

Adam Simmons , MPH;

David McDonnell , MD;

Rene Kahn , MD, PhD;

Jiani Yin , PhD;

Vasudev Bhupathi , MBA;

10/08/2020

A Combination of Olanzapine and Samidorphan in Adults With Schizophrenia and Bipolar I Disorder: Overview of Clinical Data

Objectives: Olanzapine effectively treats schizophrenia and bipolar I disorder (BD-I); however, its use is hindered by significant weight gain. A combination of olanzapine and samidorphan...

Mark Todtenkopf , PhD;

Lauren DiPetrillo , PhD;

Hannah Cummings , PhD;

Leslie Citrome , MD;

Adam Simmons , MPH;

David McDonnell , MD;

Ying Jiang , PhD;

Lei Sun , PhD;

Christine Graham , PhD;

Bernard Silverman , MD;

10/08/2020

A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients With Acute Exacerbation of Schizophrenia

Background: ALKS 3831, under development for the treatment of schizophrenia, is composed of olanzapine and samidorphan. In a prior study, samidorphan mitigated olanzapine-associated weigh...

Ying Jiang , PhD;

Bernard Silverman , MD;

Lauren DiPetrillo , PhD;

Steven Potkin , MD;

Adam Simmons , MPH;

David McDonnell , MD;

03/01/2019